✨ Free AI Report
BioXcel Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview BioXcel Therapeutics, Inc.
Research Preview

BioXcel Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

BioXcel Therapeutics is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The company's lead product IGALMI is a sublingual film for the acute treatment...

Analyst-debate audio for BioXcel Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for BioXcel Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
BioXcel Therapeutics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
5/ 10Mixed

Cyborg Score thesis

Analysts have a consensus rating of Strong Buy with an average price target of $26.67, forecasting a 1,415% increase in stock...

Read the full analyst-debate transcript →
Industry Biopharmaceutical (Neuroscience & Immuno-Oncology)
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest BioXcel Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

BioXcel Therapeutics, Inc. Overview

Pro stress-test →

BioXcel Therapeutics is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The company's lead product IGALMI is a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company plans to submit an sNDA in early Q1 2026 seeking FDA approval for at-home use of IGALMI for agitation associated with bipolar disorders or schizophrenia.

Strategic Profile

Pro stress-test →

The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. Its wholly owned subsidiary, OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology. The company targets a large market opportunity with an estimated 57-77 million annual at-home agitation episodes in the U.S.

Competitive Landscape

Pro stress-test →

BioXcel positions IGALMI as an at-home treatment option where there are currently no FDA-approved options. The company competes in the neuropsychiatric agitation treatment market against hospital and emergency-based care settings, as well as emerging digital health solutions for acute psychiatric conditions.

Industry Context

BioXcel Therapeutics, Inc. operates in Biopharmaceutical (Neuroscience & Immuno-Oncology).

Key facts

Founded: 2014 · Headquarters: New Haven, United States · Revenue: $0.752M · Market cap: $38.71M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on BioXcel Therapeutics, Inc..

+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when BioXcel Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Intramuscular Injectable AntipsychoticsIn-clinic agitation treatments→Emergency Department/HospitalizationCurrent standard of care for acute agitation→Oral AntipsychoticsTraditional psychiatric medications→

Compare BioXcel Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

BioXcel Therapeutics, Inc. operates in Biopharmaceutical (Neuroscience & Immuno-Oncology). See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical (Neuroscience & Immuno-Oncology) research →
NEW · MCP server

Ask your AI assistant about BioXcel Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare BioXcel Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did BioXcel Therapeutics, Inc. do this quarter?”
“Is BioXcel Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does BioXcel Therapeutics, Inc. do?+
BioXcel Therapeutics is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The company's lead product IGALMI is a sublingual film for the acute treatment...
What is BioXcel Therapeutics, Inc.'s Cyborg Score?+
BioXcel Therapeutics, Inc. has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are BioXcel Therapeutics, Inc.'s main competitors?+
Named competitors include Intramuscular Injectable Antipsychotics, Emergency Department/Hospitalization, Oral Antipsychotics. The full competitive landscape is in the AskCyborg report.
How can I get the full BioXcel Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the BioXcel Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track BioXcel Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.